Paclitaxel, or Taxol, is an old standby drug in the oncologist’s tool belt. Yet only about half of breast cancer patients treated with the drug see their tumors shrink or disappear, and doctors and researchers have no way of knowing which patients will benefit. But that may soon change. Published Sept. 8 in Science Translational